See more : RHI Magnesita N.V. (RHIM.VI) Income Statement Analysis – Financial Results
Complete financial analysis of Catalyst Pharmaceuticals, Inc. (CPRX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Catalyst Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Innovaro, Inc. (INNI) Income Statement Analysis – Financial Results
- AGC Networks Limited (AGCNET.NS) Income Statement Analysis – Financial Results
- Builders FirstSource, Inc. (BLDR) Income Statement Analysis – Financial Results
- Robinsons Retail Holdings, Inc. (RRETY) Income Statement Analysis – Financial Results
- Collective Mining Ltd. (CNL.V) Income Statement Analysis – Financial Results
Catalyst Pharmaceuticals, Inc. (CPRX)
About Catalyst Pharmaceuticals, Inc.
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company also develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3, as well as to treat hereditary neuropathy with liability to pressure palsies. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 398.20M | 214.20M | 140.83M | 119.07M | 102.31M | 500.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 488.96K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 84.53M | 34.39M | 21.88M | 17.04M | 14.76M | 19.92M | 45.69K | 43.41K | 34.47K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 313.67M | 179.81M | 118.95M | 102.03M | 87.55M | -19.42M | -45.69K | -43.41K | -34.47K | 0.00 | 0.00 | 0.00 | 0.00 | 488.96K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 78.77% | 83.94% | 84.46% | 85.69% | 85.57% | -3,883.84% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 93.15M | 19.79M | 16.94M | 16.50M | 18.84M | 19.92M | 11.38M | 11.37M | 11.80M | 10.12M | 8.10M | 2.66M | 3.38M | 2.31M | 5.10M | 8.71M | 2.99M | 989.14K | 1.46M | 378.25K | 0.00 | 137.68K |
| General & Administrative | 47.02M | 28.71M | 23.48M | 20.67M | 33.58M | 15.88M | 7.30M | 7.91M | 8.60M | 4.47M | 2.21M | 2.56M | 2.70M | 2.21M | 2.18M | 2.18M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 86.69M | 29.47M | 26.15M | 23.57M | 3.30M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 133.71M | 58.18M | 49.63M | 44.23M | 36.88M | 15.88M | 7.30M | 7.91M | 8.60M | 4.47M | 2.21M | 2.56M | 2.70M | 2.21M | 2.18M | 2.18M | 2.04M | 1.91M | 359.28K | 164.70K | 0.00 | 0.00 |
| Other Expenses | 0.00 | 2.88M | 282.00K | 586.90K | 1.59M | 1.29M | 454.16K | 321.61K | 100.39K | 76.23K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -428.62K | 118.27K |
| Operating Expenses | 259.43M | 77.97M | 66.56M | 60.73M | 55.72M | 35.80M | 18.68M | 19.28M | 20.40M | 14.59M | 10.31M | 5.22M | 6.08M | 4.51M | 7.28M | 10.89M | 5.03M | 2.90M | 1.82M | 542.96K | -428.62K | 255.95K |
| Cost & Expenses | 311.39M | 112.37M | 88.45M | 77.77M | 70.48M | 35.80M | 18.68M | 19.28M | 20.40M | 14.59M | 10.31M | 5.22M | 6.08M | 4.51M | 7.28M | 10.89M | 5.03M | 2.90M | 1.82M | 542.96K | -428.62K | 255.95K |
| Interest Income | 0.00 | 0.00 | 282.00K | 587.00K | 1.59M | 1.29M | 454.16K | 321.61K | 100.39K | 76.23K | 47.42K | 14.98K | 10.99K | 17.86K | 33.47K | 329.35K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.29M | 454.16K | 321.61K | 100.39K | 76.23K | 47.42K | 14.98K | 10.99K | 17.86K | 33.47K | 329.35K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 32.88M | 1.49M | 484.00K | 885.32K | 297.73K | 37.98K | 45.69K | 43.41K | 34.47K | 26.57K | 22.48K | 10.89K | 42.84K | 25.74K | 30.23K | 32.76K | 15.76K | 4.93K | 1.37K | 366.00 | 0.00 | 0.00 |
| EBITDA | 119.69M | 101.84M | 52.39M | 41.30M | 31.82M | -35.26M | -18.49M | -18.03M | -20.46M | -13.57M | -8.40M | -6.35M | -6.35M | -4.00M | -7.21M | -10.53M | -5.01M | -2.72M | -1.82M | -542.59K | -428.62K | -255.95K |
| EBITDA Ratio | 30.06% | 47.54% | 37.20% | 34.69% | 31.11% | -7,059.03% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -817.75% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | 86.81M | 101.84M | 52.39M | 41.30M | 31.82M | -35.30M | -18.68M | -19.28M | -20.40M | -14.59M | -10.31M | -5.22M | -6.08M | -4.02M | -7.28M | -10.89M | -5.03M | -2.90M | -1.82M | -542.96K | -428.62K | -255.95K |
| Operating Income Ratio | 21.80% | 47.54% | 37.20% | 34.69% | 31.11% | -7,059.03% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -823.01% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 7.70M | 2.88M | 282.00K | 586.90K | 1.59M | 1.29M | 267.26K | 1.21M | 165.39K | -917.63K | -1.84M | 1.14M | -308.92K | 17.86K | 33.47K | 329.35K | 887.64K | 172.87K | 16.79K | 3.14K | 0.00 | 0.00 |
| Income Before Tax | 94.51M | 104.72M | 52.67M | 41.89M | 33.41M | -34.00M | -18.41M | -18.07M | -20.23M | -15.51M | -12.15M | -4.08M | -6.39M | -4.01M | -7.24M | -10.56M | -4.14M | -2.73M | -1.81M | -539.82K | 0.00 | -255.95K |
| Income Before Tax Ratio | 23.73% | 48.89% | 37.40% | 35.18% | 32.66% | -6,800.70% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -819.36% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 23.10M | 21.64M | 13.19M | -33.09M | 1.53M | 2.58M | 141.22K | -929.54K | -99.47K | 993.87K | 1.84M | -1.16M | 308.92K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 428.62K | 0.00 |
| Net Income | 71.41M | 83.08M | 39.48M | 74.98M | 31.88M | -34.00M | -18.41M | -18.07M | -20.23M | -15.51M | -12.15M | -4.08M | -6.39M | -4.01M | -7.24M | -10.56M | -4.14M | -2.73M | -1.81M | -539.82K | -428.62K | -255.95K |
| Net Income Ratio | 17.93% | 38.79% | 28.03% | 62.97% | 31.16% | -6,800.70% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -819.36% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | 0.67 | 0.80 | 0.38 | 0.72 | 0.31 | -0.33 | -0.21 | -0.22 | -0.25 | -0.24 | -0.27 | -0.14 | -0.29 | -0.22 | -0.48 | -0.81 | -0.33 | -0.36 | -0.29 | -0.18 | -0.15 | -0.11 |
| EPS Diluted | 0.63 | 0.75 | 0.37 | 0.71 | 0.30 | -0.33 | -0.21 | -0.22 | -0.25 | -0.24 | -0.27 | -0.14 | -0.29 | -0.22 | -0.48 | -0.81 | -0.33 | -0.36 | -0.29 | -0.18 | -0.15 | -0.11 |
| Weighted Avg Shares Out | 106.28M | 103.37M | 103.38M | 103.51M | 102.94M | 102.63M | 85.80M | 82.88M | 80.86M | 64.14M | 45.45M | 30.03M | 21.73M | 18.58M | 15.07M | 13.01M | 12.53M | 7.69M | 6.20M | 2.92M | 2.92M | 2.36M |
| Weighted Avg Shares Out (Dil) | 113.75M | 111.38M | 107.80M | 106.24M | 106.02M | 102.63M | 85.80M | 82.88M | 80.86M | 64.14M | 45.45M | 30.03M | 21.73M | 18.58M | 15.07M | 13.01M | 12.53M | 7.69M | 6.20M | 2.92M | 2.92M | 2.36M |
Catalyst Pharmaceuticals Donates $100,000 to the American Red Cross Hurricane Helene Relief Efforts
CORAL GABLES, Fla., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "the Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel therapies for patients with rare diseases, today announced that it has...
New Strong Buy Stocks for October 8th
CPRX, HCI, DXC, CRAI and CRUS have been added to the Zacks Rank #1 (Strong Buy) List on October 8, 2024.
CPRX or STVN: Which Is the Better Value Stock Right Now?
Investors interested in Medical - Drugs stocks are likely familiar with Catalyst Pharmaceutical (CPRX) and Stevanato Group (STVN). But which of these two stocks is more attractive to value investors?
Catalyst (CPRX) is on the Move, Here's Why the Trend Could be Sustainable
If you are looking for stocks that are well positioned to maintain their recent uptrend, Catalyst (CPRX) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Catalyst (CPRX) Upgraded to Buy: What Does It Mean for the Stock?
Catalyst (CPRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Catalyst Pharmaceuticals to Participate in the BofA Securities CNS Therapeutics Virtual Conference 2024
CORAL GABLES, Fla., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases today announced that...
Catalyst Pharmaceuticals Announces Sub-Licensee DyDo Pharma Received Approval to Commercialize FIRDAPSE® in Japan
CORAL GABLES, Fla., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today announced that its sub-licensee in...
Santhera Announces Half-Year 2024 Financial Results and Provides Corporate Update
Ad hoc announcement pursuant to Art. 53 LR A conference call will be held on September 12, 2024, at 14:30 CEST / 13:30 BST / 08:30 EDT.
Why Is Catalyst (CPRX) Up 8.3% Since Last Earnings Report?
Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock?
Catalyst Pharmaceuticals to Participate in Upcoming Investor Conferences
CORAL GABLES, Fla., Aug. 20, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that...
Source: https://incomestatements.info
Category: Stock Reports